KRAS Inhibitor Market: By Cancer Type (Breast Cancer, Pancreatic Cancer, Colon Cancer, Lung Cancer, and Others), By Application (Development and Drug Formulation, Development of Molecular Diagnostics, Disease Diagnostics, Drug Discovery and Development, and Others), By End User (Ambulatory Surgical Centers, Academic and Cancer Research Institute, Clinical Laboratories, Contract Research Organizations (CRO), and Others), and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

KRAS Inhibitor Market was valued at USD 90.6 million in 2023 and is expected to grow to USD 682.3 million by 2029, growing at a 23.3% CAGR from 2024 to 2030. KRAS also known as Kirsten rat sarcoma virus, is a gene that provides for making a protein called K-RAS. The mutated form has been found in some types of cancer such as lung cancer, breast cancer, and pancreatic cancer, and is responsible due to self-activation capacity when guanosine exchange factor (GEF) protein displaces GDP from the nucleotide-binding site. The KRAS market-driven pancreatic cancer is extremely fatal.

According to the World Health Organization (WHO), Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon rectum, and prostate cancers. Rising demand for chemotherapy, radiation therapy, and other therapies accelerated the market, introduction of novel drug development drives the market growth. The diagnostic procedure followed in cancer detection, Bio makers testing which informs therapy options during diseases, and demand for novel drugs and FDA approval as a companion diagnostic application for identification of non-small cell lung cancer may be eligible for treatment with Lumakras creates opportunities in the market. lack of understanding and regarding the benefits of KRAS may limit the expansion in the market which is restraints in the market growth. Geographically, North America held the major market share in 2022 and is expected to dominate the global KRAS inhibitor market in the forecasted years.

KRAS Inhibitor Market Key Developments:
  • In December 2022, the FDA Approved Adagrasib for Locally Advanced or Metastatic KRAS G12C+ NSCLC
  • In September 2022, Amgen announced detailed results from the global Phase 3 CodeBreaK 200 trial, which showed once-daily oral LUMAKRAS®/LUMYKRAS® (sotorasib) led to significantly superior progression-free survival and a significantly higher objective response rate in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC)

KRAS Inhibitor Market Summary

Study Period


Base Year




Largest Market

North America

Fastest Growing Market

North America
KRAS Inhibitor Market Dynamics

The increasing prevalence of cancer patients across the world is the major market driver in the KRAS inhibitor Market during the forecast period. When mutation in KRAS occurs, greater and cells grow without symptoms causing cancer in the body, the rising incidence of breast cancer and prostate cancer, accelerated development of novel drugs. FDA-approved SOTORASIB to treat non-small lung cancer that has specific mutation.  Hence, this will drive the market growth at a significant rate.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies.
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

KRAS Inhibitor Market Segmentation

By Cancer Type
  • Breast Cancer
  • Pancreatic Cancer
  • Colon Cancer
  • Lung Cancer
  • Others
By Application
  • Development and Drug Formulation
  • Development of Molecular Diagnostics
  • Disease Diagnostics
  • Drug Discovery and Development
  • Others
By End User
  • Ambulatory Surgical Centers
  • Academic and Cancer Research Institute
  • Clinical Laboratories
  • Contract Research Organizations (CRO)
  • Others

Frequently Asked Questions

The KRAS inhibitor market size is expected to be valued at USD 90.6 million in 2023

The leading players in the KRAS inhibitor market are F. Hoffmann-La Roche Ltd, Qiagen, Agilent Technologies Inc., Illumina Inc., Thermo Fisher Scientific Inc., Abbott, NimaGen BV, Agena Bioscience Inc., BML Inc., Takara Bio Inc., New England Biolabs, Amoy Diagnostics Co Ltd, Panagene, EntroGen, Sysmex Corporation, and Biocartis

Historic years considered for the market study are 2019 through 2023, 2023 is considered as the base year for market estimation and Seven years forecast is presented from 2024 – 2030

  • Hoffmann-La Roche Ltd
  • Qiagen
  • Agilent Technologies Inc.
  • Illumina Inc
  • Thermo Fisher Scientific Inc.
  • Abbott
  • NimaGen BV
  • Agena Bioscience Inc.
  • BML Inc.
  • Takara Bio Inc.
  • New England Biolabs
  • Amoy Diagnostics Co Ltd
  • Panagene
  • EntroGen
  • Sysmex Corporation
  • Biocartis

Adjacent Markets